INBS (Intelligent Bio) Return on Sales by Gross Profit

Relative gross margin demonstrates the leadership position of Intelligent Bio Solutions (INBS), whose patents create a protected B2B channel in the non-invasive sweat analysis niche. However, the current status is 26.50, highlighting a liquidity deficit and reliance on borrowed funds due to promotion costs. Meanwhile, Intelligent Bio Solutions (INBS) is expanding its line of rapid tests, ensuring a steady stream of corporate orders from employers.
Comprehensive metric breakdowns and analytics for Intelligent Bio (INBS)

Intelligent Bio Solutions (INBS) leverages significant pricing power within the non-invasive rapid testing segment, allowing the company to dictate market terms due to low demand elasticity. This model is quantified through the spread between revenue and direct production costs, where the gross margin reflects the efficiency of converting unique technology into net operating cash flow and fundamental capital stability.